Synthetic antimalarials;Antipaludéens de synthèse

Annales de Dermatologie et de Venereologie

Volumn 132, Issue 8-9 I, 2005, Pages 665-674

  Fardet, L ^a   Revuz, J ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ATROPINE; CHLOROQUINE; HYDROXYCHLOROQUINE; QUINIDINE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHMA; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LUPUS ERYTHEMATOSUS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOTODERMATOSIS; POLYMYOSITIS; PORPHYRIA CUTANEA TARDA; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCHIZOPHRENIA; SJOEGREN SYNDROME; TEMPORAL ARTERITIS;

EID: 24944471694     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0151-9638(05)79414-x     Document Type: Review

References (115)

1. Slater AF. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther 1993;57:203-35.
2. Landewè RB, Miltenburg AM, Verdonk MJ, Verweij CL, Breedveld FC, Daha MR, et al. Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness. Clin Exp Immunol 1995;102:144-51.
3. Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. J Rheumatol 1993;20:803-8.
4. Van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol 1997;24:55-60.
5. Chandra S, Adhikary G, Sikdar R, Sen PC. The in vivo inhibition of transport enzyme activities by Chloroquine in different organs of rat is reversible. Mol Cell Biochem 1992:118:15-21.
6. 2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis. Gen Pharmacol 1998;30:357-66.
7. Labro MT, Babin-Chevaye C. Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro. Antimicrob Agents Chemother 1988;32:1124-30.
8. Ferrante A, Rowan-Kelly B, Seow WK, Thong YH. Depression of human polymorphonuclear leucocyte function by anti-malarial drugs. Immunology 1986;58:125-30.
9. Colombo MI, Bertini F. Properties of binding sites for chloroquine in liver lysosomal membranes. J Cell Physiol 1988;137:598-602.
10. Chigo D, Aldieri E, Todde R, Costamagna C, Garbarino G, Pescarmona G, et al. Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells. J Clin Invest 1998; 102:595-605.
11. Krogstad DJ, Schlesinger PH. Acid-vesicle function, intracellular pathogens, and the action of chloroquine against Plasmodium falciparum. N Engl J Med 1987;317:542-9.
12. Cross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. Ann Rev Physiol 1995;57:737-69.
13. Meng XW, Feller JM, Ziegler JB, Pittman SM, Ireland CM. Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum 1997;40:927-35.
14. Sjolin-Forsberg C, Berne B, Johansson M, Olsson MJ, Rollman O. Differential uptake of chloroquine by human keratinocytes and melanocytes in culture. Arch Dermatol Res 1996;288:211-5.
15. Cottlieb RA, Nordberg J, Skowronski E, Babior BM. Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proc Natl Acad Sci USA 1996;93:654-8.
16. Nguyen TQ, Capra JD, Sontheimer RD. 4-Aminoquinoline antimalarials enhance UV-B induced c-jun transcriptional activation. Lupus 1998; 7:148-53.
17. Sjolin-Forsberg C, Berne B, Eggelte TA, Karlsson-Parra A. In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients. Acta Derm Venereol 1995;75:228-31.
18. Espinola RG, Pierangeli SS, Ghara AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002;87:518-22.
19. Johansson E, Forsberg K, Johnsson H. Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis 1981;10:89-96.
20. Costedoat-Chalumeau N, Amoura Z, Aymard G, Le TH, Wechsler B, Vauthier D, et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 2002;46:1123-4.
21. Essien EE, Afamefuna GC. Chloroquine and its metabolites in human cord blood, neonatal blood, and urine after maternal medication. Clin Chem 1982;28:1148-52.
22. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong du LT, Sebbough D, Wechsler B, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48:3207-11.
23. Levy M, Buskila D, Gladman DD, Urowitz MB, Koren G. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991;8:174-8.
24. Parke A, West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996;23:1715-8.
25. Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996;55:486-8.
26. Motta M, Tincani A, Faden D, Zinzini E, Chirico G. Antimalarial agents in pregnancy. Lancet 2002;359:524-5.
27. Wolfe MS, Cordero JF. Safety of chloroquine in chemosuppression of malaria during pregnancy. Br Med J (Clin Res Ed) 1985;290:1466-7.
28. McGready R, Thwai KL, Cho T, Looareesuwan S, White NJ, Nosten F. The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy. Trans R Soc Trop Med Hyg 2002;96:180-4.
29. Pfau G, Westphal S, Dietzmann K, von Bossanyi P, Augustin W. Chloroquine effects on intrauterine and postnatal dendritic maturation of hippocampal neurons and on lipid composition of the developing rat brain. Exp Toxicol Pathol 1997;49:361-7.
30. Okanlawon AO, Ejiwunmi AB, Dada MO, Ashiru OA. Chloroquine-induced retardation of foetal lung maturation in rats. Afr J Med Med Sci 1993;22:61-7.
31. Meerbach W, Grabner R, Muller U, Zimmermann W. Influence of imipramine and chloroquine on lung phospholipid content and lung structure in newborn rats. Exp Pathol 1987;32:225-32.
32. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996;5:511-5.
33. McLachlan AJ, Tett SE, Cutler DJ, Day RO. Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques. Br J Clin Pharmacol 1993;36:405-11.
34. Tett S, Day R, Cutler D. Hydroxychloroquine relative bioavailability: within subject reproducibility. Br J Clin Pharmacol 1996;41:244-6.
35. Akintonwa A, Gbajumo SA, Mabadeje AF. Placental and milk transfer of chloroquine in humans. Ther Drug Monit 1988;10:147-9.
36. Nation RL, Hackett LP, Dusci LJ, Ilett KF. Excretion of hydroxychloroquine in human milk. Br J Clin Pharmacol 1984:117:368-9.
37. Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992;127:513-8.
38. Chieregato G, Peroni A, Castellani L, Nigro MA. Effects of hydroxychloroquine on 'band test' in discoid lupus erythematosus. Dermatologica 1990;180:130-2.
39. Callen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch Dermatol 1982;118:412-6.
40. Dubois EL. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum 1978;1:33-51.
41. Merwin CF, Winkelmann RK. Antimalarial drugs in the therapy of lupus erythematosus. Proc Mayo Clin 1962;37:253-68.
42. Winkelmann RK, Merwin CF, Brunsting LA. Antimalarial therapy of lupus erythematosus. Ann Intern Med 1961;55:772-6.
43. Lipsker D, Piette JC, Cacoub P, Godeau P, Frances C. Chloroquinequinacrine association in resistant cutaneous lupus. Dermatology 1995; 190:257-8.
44. Feldmann R, Salomon D, Saurat JH. The association of the two anti-malarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994;189:425-7.
45. Martens PB, Moder KG, Ahmed I. Lupus panniculitis: clinical perspectives from a case series. J Rheumatol 1999;26:68-72.
46. Chung HS, Hann SK. Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol 1997;24:569-72.
47. Morel P, Marinho E, Bruneau C, Civatte J, Puissant A. Les lésions cutanées profondes du lupus érythémateux. Ann Med Interne (Paris) 1986;137:320-3.
48. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001;10:401-4.
49. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998;7:80-5.
50. Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996;5:237-41.
51. Williams HJ, Egger MJ, Singer JZ, Willkens RF, Kalunian KC, Clegg DO, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol 1994; 21:1457-62.
52. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150-4.
53. Rothfield N. Efficacy of antimalarials in systemic lupus erythematosus. Am J Med 1988;85:53-6.
54. Rudnicki RD, Gresham GE, Rothfield NF. The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol 1975;2:323-30.
55. Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997;96:4380-4.
56. Erkan D, Yazici Y, Peterson MC, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41:924-9.
57. Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum 1987;30:1435-6.
58. Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990;23:487-9.
59. Siltzbach LE, Teirstein AS. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand Suppl 1964;425:302-8.
60. Valls V, Ena J, Enriquez-De-Salamanca R. Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload. J Dermatol Sci 1994;7:169-75.
61. Marchesi L, Di Padova C, Cainelli T, Reseghetti A, Di Padova F, Rovagnati P, et al. A comparative trial of desferrioxamine and hydroxychloroquine for treatment of porphyria cutanea tarda in alcoholic patients. Photodermatol 1984;1:286-92.
62. Cainelli T, Di Padova C, Marchesi L, Cori G, Rovagnati P, Podenzani SA, et al. Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda. Br J Dermatol 1983;108:593-600.
63. Wennersten C, Ros AM. Chloroquine in treatment of porphyria cutanea tarda. Long-term efficacy of combined phlebotomy and high-dose chloroquine therapy. Acta Derm Venereol Suppl (Stockh) 1982; 100:119-23.
64. Malina L, Chlumsky J. A comparative study of the results of phlebotomy therapy and low-dose chloroquine treatment in porphyria cutanea tarda. Acta Derm Venereol 1981;61:346-50.
65. Petersen CS, Thomsen K. High-dose hydroxychloroquine treatment of porphyria cutanea tarda. J Am Acad Dermatol 1992;26:614-9.
66. Tsega E, Besrat A, Damtew B, Seyoum E, Landells JW. Chloroquine in the treatment of porphyria cutanea tarda. Trans R Soc Trop Med Hyg 1981;75:401-4.
67. Freesemann A, Frank M, Sieg I, Doss MO. Treatment of porphyria cutanea tarda by the effect of chloroquine on the liver. Skin Pharmacol 1995;8:156-61.
68. Stolzel U, Kostler E, Schuppan D, Richter M, Wollina U, Doss MO, et al. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 2003;139:309-13.
69. Sallum AM, Kiss MH, Sachetti S, Resende MB, Moutinho KC, Carvalho M, et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuropsiquiatr 2002;60:889-99.
70. Jager C, Sirvent N, Rabasse N, Soler C, Sebag F, Boutte P, et al. Dermatomysosite juvénile dans la région niçoise. Ann Dermatol Venereol 2002;129:1120-4.
71. Cosnes A, Amaudric F, Gherardi R, Verroust J, Wechsler J, Revuz J, et al. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol 1995;131:1381-5.
72. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984;10:592-600.
73. Murphy GM, Hawk JL, Magnus IA. Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring. Br J Dermatol 1987;116:379-86.
74. Jansen CT. Oral carotenoid treatment in polymorphous light eruption: a cross-over comparison with oxychloroquine and placebo. Photodermatol 1985;2:166-9.
75. Corbett MF, Hawk JL, Herxheimer A, Magnus IA. Controlled therapeutic trials in polymorphic light eruption. Br J Dermatol 1982;107:571-81.
76. Rotteleur G, Thomas P, Beani JC, Jeanmougin M, Peyron JL, Marguery MC, et al. Étude prospective multicentrique de l'efficacité de l'hydroxychloroquine (Plaquenil) contre placebo dans la Lucite estivale bénigne. Rech Dermatol 1988;11:157-66.
77. Braddock SW, Kay HD, Maennle D, McDonald TL, Pirruccello SJ, Masih A, et al. Clinical and immunologic studies in reticular erythematous mucinosis and Jessner's lymphocytic infiltrate of skin. J Am Acad Dermatol 1993;28:691-5.
78. Lemley DE, Ferrans VJ, Fox LM, Satler L, Cupps TR. Cardiac manifestations of Weber-Christian disease: report and review of the literature. J Rheumatol 1991;18:756-60.
79. Sorensen RU, Abramowsky C, Stern RC. Corticosteroid-sparing effect of hydroxychloroquine in a patient with early-onset Weber-Christian syndrome. J Am Acad Dermatol 1990;23:1172-4.
80. Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells C, Tugwell P. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000;(4):CD000959.
81. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. Am J Med. 1995;98:156-68.
82. Sanders M. A review of controlled clinical trials examining the effects of antimalarial compounds and gold compounds on radiographic progression in rheumatoid arthritis. J Rheumatol 2000;27:523-9.
83. Ferraccioli GF, Salaffi F, De Vita S, Casatta L, Avellini C, Carotti M, et al. Interferon alpha-2 (IFN alpha 2) increases lacrimal and salivary function in Sjogren's syndrome patients. Preliminary results of an open pilot trial versus OH-chloroquine. Clin Exp Rheumatol 1996;14:367-71.
84. Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjogren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 1999;58:253-6.
85. Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996;5:531-6.
86. Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, et al. Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial. Ann Rheum Dis 1993; 52:360-4.
87. van Jaarsveld CH, Jahangier ZN, Jacobs JW, Blaauw AA, van Albada-Kuipers GA, ter Borg EJ, et al. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. Rheumatology (Oxford) 2000;39:1374-82.
88. Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 1997;56:188-90.
89. Cullen AP, Chou BR. Keratopathy with low dose chloroquine therapy. J Am Optom Assoc 1986;57:368-72.
90. Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, et al. Ocular toxicity of chloroquine among Thai patients. Int J Dermatol 1999;38:934-7.
91. Morsman CD, Livesey SJ, Richards IM, Jessop JD, Mills PV. Screening for hydroxychloroquine retinal toxicity: is it necessary? Eye 1990;4:572-6.
92. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983;75:40-5.
93. Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997;40:1482-6.
94. Araiza-Casillas R, Cardenas F, Morales Y, Cardiel MH. Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 2004;13:119-24.
95. Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996;55:187-9.
96. Kay EA, Rees JA, Jayson MI. The prescribing of chloroquine and hydroxychloroquine by consultant rheumatologists in the UK. Br J Rheumatol 1987;26:375-8.
97. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology 2003:110:1321-6.
98. Silman A, Shipley M. Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Br J Rheumatol 1997; 36:599-601.
99. Easterbrook M. Screening for antimalarial toxicity: current concepts. Can J Ophthalmol 2002;37:325-8, 331-4.
100. Jones SK. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 1999;140:3-7.
101. Saissi EH, Beau-Salinas F, Jonville-Bera AP, Lorette C, Autret-Leca E, Centres Regionaux de Pharmacovigilance. Médicaments associés à la survenue d'une pustulose exanthématique aiguë généralisée. Ann Dermatol Venereol 2003;130:612-8.
102. Assier-Bonnet H, Saada V, Bernier M, Clerici T, Saiag P. Acute generalized exanthematous pustulosis induced by hydroxychloroquine. Dermatology. 1996;193:70-1.
103. Boffa MJ, Chalmers RJ. Toxic epidermal necrolysis due to chloroquine phosphate. Br J Dermatol 1994;131:444-5.
104. Murphy M, Carmichael AJ. Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol 2001;26:457-8
105. Erratum in: Clin Exp Dermatol 2001;26:560.
106. Leckie MJ, Rees RC. Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis. Rheumatology 2002;41:473-4.
107. Ortel B, Sivayathorn A, Honigsmann H. An unusual combination of phototoxicity and Stevens-Johnson syndrome due to antimalarial therapy. Dermatologica 1989;178:39-42.
108. Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999;455:221-5.
109. Metayer I, Balguerie X, Courville P, Lauret P, Joly P. Photodermies photo-induites par l'hydroxychloroquine: 4 cas. Ann Dermatol Venereol 2001;128:729-31.
110. Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol. 2000;27:2927-31.
111. Baguet JP, Tremel F, Fabre M. Chloroquine cardiomyopathy with conduction disorders. Heart 1999;81:221-3.
112. Seideman P, Albertioni F, Beck O, Eksborg S, Peterson C. Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity. Arthritis Rheum 1994;37:830-3.
113. Carmichael SJ, Beal J, Day RO, Tett SE. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 2002;29:2077-83.
114. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000;42:983-7.
115. Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998;25:1716-9.